Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug following the Food and Drug Administration's threat to restrict access to the ingredients needed to copy popular weight-loss medications.
Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then the FDA said Friday that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound.
